[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340482-105":59,"doc-detail-340482-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","assessment-of-mirvetuximab-soravtansine-immunogenicity-in-patients-with-folate-receptor-alpha-positive-ovarian-cancer","Assessment of mirvetuximab soravtansine immunogenicity in patients with folate receptor alpha-positive ovarian cancer","","Aim: Evaluate the immunogenicity of mirvetuximab soravtansine (MIRV), an antibody-drug conjugate, in folate receptor alpha-positive ovarian cancer across four clinical studies. Methods: Develop and validate an assay for antidrug antibodies (ADAs) and a cell-based assay for neutralizing anti-MIRV antibodies (NAbs). Assess both ADAs and NAbs in 734 patients. Results: MIRV showed low immunogenicity; 7.8% had treatment-emergent ADAs and 0.5% had treatment-enhanced ADAs, with comparable MIRV trough levels in ADA-positive and ADA-negative groups. Limited NAb data precluded conclusions on efficacy impact. Conclusion: The assays reliably detected MIRV ADAs and NAbs and support ongoing monitoring in future trials.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/assessment-of-mirvetuximab-soravtansine-immunogenicity-in-patients-with-folate-receptor-alpha-positive-ovarian-cancer/340482/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/assessment-of-mirvetuximab-soravtansine-immunogenicity-in-patients-with-folate-receptor-alpha-positive-ovarian-cancer/340482.png","ImageObject",300,407,{"name":92,"@type":93},"Seraphina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What question does this study address about mirvetuximab soravtansine (MIRV)?","Question",{"text":113,"@type":114},"It evaluates how immunogenic MIRV is in patients with folate receptor alpha-positive ovarian cancer, focusing on whether patients develop antidrug antibodies or neutralizing antibodies after treatment.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were antidrug antibodies (ADAs) and neutralizing antibodies (NAbs) measured?",{"text":118,"@type":114},"A validated assay was developed to detect ADAs against MIRV, and a validated cell-based method was developed to detect neutralizing anti-MIRV antibodies (NAbs). Both were assessed across four clinical studies.",{"name":120,"@type":111,"acceptedAnswer":121},"What were the key findings regarding ADA frequency and drug exposure?",{"text":122,"@type":114},"MIRV showed low immunogenicity, with 7.8% treatment-emergent ADAs and 0.5% treatment-enhanced ADAs. MIRV trough concentrations were comparable between ADA-negative and ADA-positive individuals.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},340482,1790179694,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},962075114101,"https://ap-avatar.wpscdn.com/avatar/e000253a75eb197efd?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780044092746381165","RESEARCH ARTICLE     \nAssessment of mirvetuximab soravtansine immunogenicity in patients with folate receptor alpha-positive ovarian cancer  \nFengying Zhu* , a, Ya-Ping Tub, Callum Slossc and Yuemei Wangd  \na Bioanalysis, ImmunoGen, Waltham, MA 02451, USA; b Clinical Pharmacology, ImmunoGen, Waltham, MA 02451, USA; cTranslational Science, ImmunoGen, Waltham, MA 02451, USA; d Biostatistics, ImmunoGen, Waltham, MA 02451, USA  \nABSTRACT  \nAim: The aim of this research was to evaluate the immunogenicity of mirvetuximab soravtansine (MIRV), an antibody-drug conjugate in patients with folate receptor alpha-positive ovarian cancer across four clinical studies.  \nMaterials & methods: An assay was developed and validated for the detection of antidrug antibodies (ADAs) against MIRV. A cell-based method was also developed and validated for the detection of neutralizing anti-MIRV antibodies (NAbs) . Both ADAs and NAbs were assessed across four clinical studies in 734 patients.  \nResults: Across studies, MIRV demonstrated low immunogenicity with 7.8% of patients with treatment-emergent ADAs, 7.2% with treatment-unaffected ADAs, and 0.5% with treatmentenhanced ADAs. MIRV trough concentrations were comparable in ADA-negative and ADA-positive individuals. Limited data suggest that MIRV ADAs may be associated with decreased efficacy. Due to the very limited number of NAb-positive individuals, no conclusions could be drawn on the effect of NAb on efficacy.  \nConclusion: Both the validation tests and the data from the MIRV clinical studies demonstrated that these assays were suitable and reliable for the detection of MIRV ADAs and NAbs. These validated assays will continue to be used to monitor MIRV immunogenicity in future clinical trials.  \nPLAIN LANGUAGE SUMMARY  \nMirvetuximab soravtansine (MIRV) is a new drug of cancer treatment that targets a protein called folate receptor alpha, which is often found in certain ovarian cancers that do not respond to platinum-based therapies. To check if patients’ immune systems react to this drug, we developed tests to look for antibodies that may form against MIRV. These antibodies can affect how well the drug works.  \nThe study looked at 734 patients in four different clinical trials. It found that MIRV triggered an immune response in only a small number of patients – 7.8% developed new antibodies after starting treatment. However, most of these antibodies did not seem to impact the effectiveness of the drug, and patients with or without antibodies had similar levels of the drug in their bodies. Some data hinted that having antibodies might slightly reduce how well the drug works, but there were not enough patients who developed these antibodies to be certain. Another test was done to check if certain antibodies blocked MIRV from working, but very few patients (31 out of 734) had these, so no conclusions could be made.  \nOverall, the tests were shown to work well and will continue to be used in future studies to monitor how patients’immune systems respond to MIRV.  \nARTICLE HISTORY  \nReceived 3 July 2024  \nAccepted 18 September 2024  \nKEYWORDS  \nantidrug antibody;  \nantibody-drug conjugate; immunogenicity; MIRV; neutralizing antibody  \nCONTACT Fengying Zhu Tel.: +781 290 9322;  [fengying.zhu@abbvie.com](fengying.zhu@abbvie.com)  \n Supplemental data for this article can be accessed at [https://doi.org/10.1080/17576180.2024.2407228](https://doi.org/10.1080/17576180.2024.2407228)[ ](https://doi.org/10.1080/17576180.2024.2407228)© 2024 ImmunoGen, Inc. Published by Informa UK Limited, trading as Taylor & Francis Group  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License  \n([http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transform","cbCaiaeLSPKvovMO","https://ap.wps.com/l/cbCaiaeLSPKvovMO","pdf",1494750,13,"English","# Background\n# Materials & methods\n## ADA and NAb assay development and validation\n# Results\n# Conclusion\n# Plain language summary\n# Article history\n# Keywords","[{\"question\":\"What question does this study address about mirvetuximab soravtansine (MIRV)?\",\"answer\":\"It evaluates how immunogenic MIRV is in patients with folate receptor alpha-positive ovarian cancer, focusing on whether patients develop antidrug antibodies or neutralizing antibodies after treatment.\"},{\"question\":\"How were antidrug antibodies (ADAs) and neutralizing antibodies (NAbs) measured?\",\"answer\":\"A validated assay was developed to detect ADAs against MIRV, and a validated cell-based method was developed to detect neutralizing anti-MIRV antibodies (NAbs). Both were assessed across four clinical studies.\"},{\"question\":\"What were the key findings regarding ADA frequency and drug exposure?\",\"answer\":\"MIRV showed low immunogenicity, with 7.8% treatment-emergent ADAs and 0.5% treatment-enhanced ADAs. MIRV trough concentrations were comparable between ADA-negative and ADA-positive individuals.\"}]","Assessment of mirvetuximab soravtansine immunogenicity in patients with folate receptor alpha-positive ovarian cancer | PDF",1790036822,33,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bb6303db2b30953f56707ccef4ed53e4.webp",983,1272,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c4a2fd6430b80e559a184dd5ff8dfd3b.webp",982,1270,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9c817e97a9e5fd7238c85a6a7d372bf7.webp",981,1269,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c617353a0f242a1ba15eac9fd5e520ff.webp",980,1268]